MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

Search

PerkinElmer Inc

Gesloten

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken

By Trading Economics

Inkomsten

-53M

42M

Verkoop

-65M

665M

K/W

Sectorgemiddelde

39.236

50.291

EPS

1.01

Dividendrendement

0.29

Winstmarge

6.268

Werknemers

11,000

EBITDA

-50M

173M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+21.21% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.29%

2.40%

Volgende Winsten

28 jul 2025

Volgende dividenddatum

8 aug 2025

Volgende Ex Dividend datum

18 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-2.8B

11B

Vorige openingsprijs

0

Vorige sluitingsprijs

0

Nieuwssentiment

By Acuity

28%

72%

37 / 380 Rangschikking in Healthcare

PerkinElmer Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 jul 2025, 23:09 UTC

Winsten

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 jul 2025, 19:16 UTC

Acquisities, Fusies, Overnames

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 jul 2025, 23:47 UTC

Marktinformatie

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 jul 2025, 23:41 UTC

Marktinformatie

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 jul 2025, 22:23 UTC

Acquisities, Fusies, Overnames

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 jul 2025, 22:23 UTC

Acquisities, Fusies, Overnames

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 jul 2025, 22:21 UTC

Acquisities, Fusies, Overnames

James Hardie Completes Acquisition of AZEK

1 jul 2025, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

1 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

1 jul 2025, 20:24 UTC

Winsten

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 jul 2025, 19:55 UTC

Marktinformatie

Oil Futures Resume Cautious Rally -- Market Talk

1 jul 2025, 19:27 UTC

Marktinformatie

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 jul 2025, 19:12 UTC

Marktinformatie

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 jul 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 jul 2025, 18:41 UTC

Acquisities, Fusies, Overnames

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 jul 2025, 18:33 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

1 jul 2025, 18:33 UTC

Marktinformatie

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 jul 2025, 18:32 UTC

Marktinformatie

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 jul 2025, 18:22 UTC

Marktinformatie

Remittances to Mexico Down in May -- Market Talk

1 jul 2025, 17:45 UTC

Marktinformatie

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 jul 2025, 17:01 UTC

Acquisities, Fusies, Overnames

Danone Completed Acquisition of Majority Stake in Kate Farms

1 jul 2025, 16:55 UTC

Winsten

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 jul 2025, 16:27 UTC

Marktinformatie

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 jul 2025, 16:25 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 jul 2025, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

1 jul 2025, 15:48 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 jul 2025, 15:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

1 jul 2025, 15:46 UTC

Marktinformatie

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 jul 2025, 14:54 UTC

Marktinformatie

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 jul 2025, 14:49 UTC

Marktinformatie

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Peer Vergelijking

Prijswijziging

PerkinElmer Inc Prognose

Koersdoel

By TipRanks

21.21% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 117.23 USD  21.21%

Hoogste 135 USD

Laagste 100 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor PerkinElmer Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

14 ratings

9

Buy

5

Hold

0

Sell

Sentiment

By Acuity

37 / 380 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.